Promising Potential of Zentalis Pharmaceuticals’ Azenosertib in Treating Platinum-Resistant Ovarian Cancer

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report). The associated price target remains the same with $10.00.

Andrew Fein has given his Buy rating due to a combination of factors that highlight the potential of Zentalis Pharmaceuticals’ lead drug, azenosertib, in treating platinum-resistant ovarian cancer (PROC). The drug has shown promising results, particularly in patients with Cyclin E1+ tumors, as evidenced by the recent DENALI Phase 2 trial data. The trial demonstrated an objective response rate (ORR) of 34.9% and a median duration of response (mDOR) of 6.3 months, which surpasses historical benchmarks for chemotherapy in this patient population.
Moreover, the consistency of azenosertib’s efficacy across different trials, including MAMMOTH and the Phase 1 ZN-c3-001 trial, reinforces its potential as a biomarker-driven therapy. With approximately half of PROC patients exhibiting Cyclin E1 overexpression and lacking approved biomarker-specific treatments, azenosertib is well-positioned to address this unmet need. Additionally, Zentalis is actively refining its clinical trial protocols to enhance patient retention and optimize dosing, which could further improve efficacy outcomes and support potential accelerated approval.

Fein covers the Healthcare sector, focusing on stocks such as Neurocrine, Palvella Therapeutics, and Stoke Therapeutics. According to TipRanks, Fein has an average return of 1.9% and a 39.23% success rate on recommended stocks.

In another report released yesterday, Oppenheimer also reiterated a Buy rating on the stock with a $10.00 price target.